Children with Sanfilippo syndrome type A, including those with severe disease, showed stable or continuously increasing cognitive, language, and motor functions two years after dosing with the investigational gene therapy LYS-SAF302, new data from the AAVance trial showed. The therapy also maintained low levels of the disease-related biomarker heparan sulfate…
News
Sanfilippo syndrome affected the hearts of two sisters with the rare genetic disorder, without causing any of its more typical neurological symptoms, according to a case report. The case highlights the importance of recognizing — and treating — such rare non-neuronal manifestations of the disease, the researchers said. “Early…
The antidepressant fluoxetine was able to improve cognition and reduce the buildup of toxic molecules in a mouse model of Sanfilippo syndrome type A, a group of researchers in Italy has found. “We repurposed fluoxetine for potential therapeutics to treat human MPS-IIIA [Sanfilippo type A] disease,” the researchers wrote.
A team led by researchers at Lysogene has developed a system of four “stages” to describe the severity of Sanfilippo syndrome type A using insights gleaned from interviews with parents of children with the disease. The results were described in the study, “Understanding disease symptoms and…
The National Organization for Rare Disorders’ (NORD) “Living Rare, Living Stronger Patient and Family Forum” is back in person on June 26 for a day of learning and networking in Cleveland, Ohio. The event, which brings together the rare disease community, will take place at the InterContinental Cleveland Conference…
Communication challenges and mobility difficulties are among the most impactful symptoms for children with Sanfilippo syndrome, caregivers reported in a study. Results from the study, which was funded by the Cure Sanfilippo Foundation, could be used to inform outcome measures in clinical trials for potential treatments. The study,…
Ultragenyx Pharmaceutical has closed an agreement giving it global licensing, manufacturing, and commercialization rights to UX111 (formerly ABO-102), an experimental gene therapy for Sanfilippo syndrome type A being tested in the pivotal Phase 1/2 Transpher A trial. Ultragenyx will assume responsibility for UX111’s clinical program, while the therapy’s developer, …
The Cure Sanfilippo Foundation is supporting a research project that aims to characterize fruit fly models of Sanfilippo syndrome type A, and to identify genes that affect disease development in these models. The two-year study is being led by Trudy Mackay, PhD, a professor of…
Complications shortly after birth and a slow disease progression — combined with poor disease awareness — delayed a correct diagnosis of Sanfilippo syndrome type A for more than two decades in a 28-year-old man in Germany, a study says. While this type is associated with a faster progression, the…
A Russian military plane crash near Tetiana Zamorska’s home in Kyiv, Ukraine, was a sign that it was time for her and her family to leave. The treacherous, 34-hour pilgrimage that ultimately brought the group of eight by car to temporary accommodations in neighboring Poland last month was physically and emotionally difficult,…
Recent Posts
- Screen time is a lifeline for our daughter with Sanfilippo syndrome
- Physical therapy eases pain, improves life for Sanfilippo kids: Study
- Being a Sanfilippo parent means facing impossible decisions
- UX111 gene therapy shows long-term benefit in Sanfilippo type A: Trial data
- Our respite caregiver provides much-needed help
- Study says U.S. Sanfilippo societal cost will top $2B over 20 years
- Bone marrow transplant helps hand-eye coordination in Sanfilippo child
- The support system that allows my special needs child to thrive
- Enzyme therapy directly into the brain tested for Sanfilippo type D
- I’m finally seeing a therapist, 3 years after my daughter’s diagnosis